TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of the Philips MicroDose Tomosynthesis System to 2D Digital Mammography

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient is female and at least 40 years of age~* No contraindication for routine bilateral mammography~Screening Cohort~* Patient presents for a routine screening mammogram Biopsy Cohort~* Patient is scheduled for a biopsy~* Patient has a screening detected abnormality~Exclusion Criteria:~* Patient is pregnant or believes she may be pregnant; OR,~* Patient is breast feeding; OR~* Patient is unable or unwilling to give informed consent, including consent to reuse data for future research; OR,~* Patient has breast implants; OR~* Patient has previous surgical biopsy; OR~* Patient has previous breast cancer; OR~* Patient presented to screening with clinical symptoms (e.g. palpable lump, nipple discharge, nipple retraction, skin irritation or dimpling)

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Imaging on experimental tomo device (Type: OTHER): Women will have a bilateral two-view mammogram (a total of four images) with the Philips MicroDose Tomosynthesis system and a bilateral two-view mammogram (a total of four images) with an FFDM system. The order of this will be randomised.~After collecting the cases together with ground truth a readers study will be performed.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Stress Echocardiography Study With Regadenoson

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with a clinically indicated dobutamine echocardiogram showing normal wall motion at rest and abnormal wall motion with stress~* Patients with a clinically indicated dipyridamole echocardiogram showing normal perfusion and wall motion at rest and abnormal perfusion with or without abnormal wall motion with stress~Exclusion Criteria:~* Any condition precluding the safe administration of dobutamine, dipyridamole or SonoVue for echocardiography~* Pregnant or breast-feeding, or (if pre-menopausal), not practicing acceptable method of birth control

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Regadenoson alone (Type: EXPERIMENTAL): None
- Regadenoson with exercise (Type: EXPERIMENTAL): None
- Regadenoson with contrast agent (Type: EXPERIMENTAL): None
- Regadenoson with contrast agent (perfusion) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Role of WB-MRI in the Evaluation of Prostate Cancer Patients Treated With Lutetium - Prostate Specific Membrane Antigen (Lu-PSMA)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~- Patients with mCRPC enrolled in the Tumor Institute of Romagna (IRST) 185.03 Lu-PSMA protocol, performing baseline CT and WB-MRI examinations and at least one CT and WB-MRI re-evaluation.~Exclusion Criteria:~* no exclusion criteria

- Gender: MALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients with mCRPC enrolled in the Tumor Institute of Romagna (IRST) 185.03 Lu-PSMA protocol (Type: None): Patients with mCRPC enrolled in the IRST 185.03 Lu-PSMA study, performing baseline CT and WB-MRI examinations and at least one CT and WB-MRI re-evaluation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety and Efficacy of ET-01 Transplantation in Subjects With Transfusion Dependent β-Thalassaemia.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* Subject and/or subject's legal personal representative fully understand and voluntarily sign informed consent forms;~* 6\~35 years old, all gender;~* Diagnosis of transfusion dependent β-thalassemia (β-TDT) as defined by protocol;~* Eligible for autologous stem cell transplant;~* Organs in good function.~Other protocol defined Inclusion criteria may apply.~Key Exclusion Criteria:~* Subjects with associated α-thalassemia;~* Active bacterial, virus, fungal or parasitic infection, including HIV infection, HbsAg and HBV DNA positive, HCV DNA positive, or Treponema Pallidum infection;~* HLA identical sibling or unrelated donors are available;~* Prior allo-HSCT or gene therapy.~Other protocol defined Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 35 Years
- Healthy Volunteers: f

Study Arms:
- ET-01 (Type: EXPERIMENTAL): BCL11A Enhancer modified Autologous Hematopoietic Stem Cells

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Test to Determine the Effectiveness of Moisturizing Balm Used on Babies With Dry, Itchy Skin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Able to comprehend and follow the requirements of the study (including availability on scheduled visit dates)~2. Male or female of any race or ethnicity, 6 months to 47 months of age;~3. Diagnosed as having eczema~4. Willing to stop use of all non-assigned moisturizers and/or creams for the entire duration of the study~5. Child must have bedtime/sleep issues due to their dry, itchy skin~Exclusion Criteria:~1. Use of a therapeutic (over-the-counter or prescription) body wash that contains an active ingredient for eczema~2. Participation in any clinical study within 30 days of Visit 1~3. Active infection of any type at the start of the study~4. Diagnosed as having severe eczema~5. Atopic Dermatitis requiring systemic, super-potent (Class I) or potent (Class II or III) topical corticosteroids~6. Child wakes up 3 or more times during the night~7. Child is awake more than 60 minutes during the night~8. Child sleeps for less than a total of 9 hours (during the day or night)~9. Child requires greater than 2.0 mg per day of inhaled or intranasal corticosteroids

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 47 Months
- Healthy Volunteers: f

Study Arms:
- EpiCeram Skin Barrier Emulsion (Type: ACTIVE_COMPARATOR): Marketed. Apply in a thin layer to the affected skin areas two times per day (or as needed) and massage gently into the skin.
- 1% Colloidal Oatmeal Balm (Type: EXPERIMENTAL): Not Yet Marketed. Apply in a thin layer to the affected skin areas at least once at night or more if needed (anytime), and massage gently into the skin.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Use of Intranasal Ketoralac for Pain Management (Sprix)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ureteroscopic stone removal surgeries with stenting~* Age ≥ 18 years and \< 65 years~* Stable patient with stable vital signs~* Mentally competent and is able to understand consent form~Exclusion Criteria:~* Unstable patients~* Patients with multiple trauma sites~* Patients with allergies to ketorolac or any of the components in the nasal spray preparation~* Patients with active peptic ulcer disease~* History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs~* Renal disease or at risk for renal failure due to volume depletion~* Pregnant or nursing mothers~* Nasal abnormality or illness that could affect the absorption of intranasal medication (such as: nasal discharge, rhinitis, acute upper respiratory infection, acute epistaxis, nasal polyp, nasal tumor)~* Any other contraindication to the use of Sprix, or in whom use of Sprix would not be consistent with the approved package insert

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Intranasal Ketoralac (Type: EXPERIMENTAL): A single dose of Sprix (31.5 mg) will be administered to patients 20 minutes before the end of surgery. 15.75 mg of Sprix will be sprayed in each nostril.
- Placebo (Type: PLACEBO_COMPARATOR): A single dose of placebo will be administered 20 minutes before the end of surgery. 15.75 mg of the placebo will be sprayed in each nostril.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Study of HL-085 Plus Docetaxel in Patients With KRAS Mutant NSCLC

Study Design Characteristics:
- Allocation: None
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. KRAS mutation NSCLC.~2. One measurable lesion as defined by RECIST 1.1 criteria for solid tumors.~3. Chemotherapy, immunotherapy or radiotherapy ≥ 4 weeks prior to starting the study treatment.~4. Surgery (except for tumor biopsy) or severe trauma ≤ 14 days prior to starting the study treatment.~5. ECOG performance status of 0-1.~6. Life expectancy ≥ 3 months.~7. Ability to take the medicine orally.~8. Ability to understand and the willingness to sign a written informed consent document.~Exclusion Criteria:~1. Hypersensitivity to study drug ingredients or their analogues.~2. Prior therapy with MEK-inhibitor.~3. Receiving any other anti-cancer therapy at the same time .~4. Active central nervous system (CNS) lesion.~5. Bleeding symptoms at Grade 3 within 4 weeks prior to starting study treatment.~6. ECG QTcB≥480msec in screening, or history of congenital long QT syndrome；~7. Uncontrolled concomitant diseases or infectious diseases.~8. Retinal diseases (Retinal Vein Occlusion (RVO) or Retinal pigment epithelial detachment (RPED) , et al.).~9. History of HIV,HCV,HBV infection.~10. Interstitial lung disease or interstitial pneumonitis, including clinically significant radiation pneumonitis will be excluded.~11. Serum HCG test is positive.~12. Other conditions that increase the risk of study and influence the result.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- dose escalation of HL-085 plus Docetaxel (Type: EXPERIMENTAL): HL-085 will be administered as BID with specified dose. And Docetaxel will be taken as the instruction in the label ( 75mg/m2，IV).~f no Dose-limiting toxicity (DLT) occurs in the first three subjects in Cycle 1, the dose will be escalated to the next dose level; If a DLT occurs in one of the first three subjects, three additional subjects will be enrolled for the same dose cohort, and undergo the same procedures. Dose -escalation is performed based on the scheduled dose groups until DLT occurs in two or more subjects in a dose group which consists of 3 or 6 subjects.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Study Using Dexmedetomidine to Decreases Emergence Delirium in Pediatric Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ASA class 1 or 2 (healthy patient or acute illness)~* Parental willingness to participate~* Candidate for pressure-equalization tubes (PET) as determined by the ENT department~Exclusion Criteria:~* ASA class 3 or 4 (chronic illness or life-threatening illness)~* Parental refusal to participate~* Significant liver disease by history~* Allergy to dexmedetomidine or midazolam~* Nasal deformity~* Fever in the three days prior to surgery~* Nausea or vomiting~* History of hypertension~* History of cardiac dysfunction/disorder~* Diabetes mellitus

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 5 Years
- Healthy Volunteers: t

Study Arms:
- saline (Type: PLACEBO_COMPARATOR): intranasal saline will be given 30 minutes prior to surgery
- dexmedetomidine (Type: EXPERIMENTAL): 2 mcg/kg dexmedetomidine will be given intranasally 30 minutes prior to surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: S0224, Docetaxel in Treating Patients With Locally Advanced or Metastatic Penile Cancer (TERMINATED)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed epidermoid carcinoma of the penis~  * Distant metastases (M1) OR~ * Pathologically confirmed regional nodal metastases (N1-3)~* Measurable disease~  * Soft tissue disease irradiated within the past 2 months is not considered measurable disease~PATIENT CHARACTERISTICS:~Age~* Not specified~Performance status~* Zubrod 0-2~Life expectancy~* Not specified~Hematopoietic~* White blood cell (WBC) count at least 3,000/mm\^3~* Absolute granulocyte count at least 1,500/mm\^3~* Platelet count at least 100,000/mm\^3~Hepatic~* Bilirubin no greater than upper limit of normal (ULN)~* Aspartate aminotransferase (SGOT) no greater than 2.5 times ULN~  * If SGOT is greater than ULN, alkaline phosphatase must be no greater than 2.5 times ULN~* Alkaline phosphatase no greater than 4 times ULN~  * If alkaline phosphatase is greater than ULN, SGOT must be no greater than 1.5 times ULN~Renal~* Not specified~Other~* Fertile patients must use effective contraception~* No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or stage I or II cancer currently in complete remission~* No grade 2 or greater peripheral neuropathy~* No hypersensitivity to drugs formulated with polysorbate 80 (e.g., recombinant interferon alfa-2a, multivitamin infusion, etoposide, infliximab, or NovoSeven factor)~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Not specified~Chemotherapy~* No prior chemotherapy for penile cancer~Endocrine therapy~* Not specified~Radiotherapy~* See Disease Characteristics~* At least 28 days since prior radiotherapy and recovered~Surgery~* Not specified

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Home Rehabilitation Using Smart Wearable Exercise and Electrical Stimulation Device After Anterior Cruciate Ligament Reconstruction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with anterior cruciate ligament reconstruction~* Patients who are older than 19 years of age~Exclusion Criteria:~* History of surgery or traumatic injury to the uninvolved lower extremity~* Complication after ACL reconstruction surgery~* Dermatological conditions affecting the thigh~* Body mass index (BMI) greater than 40 kg/m2~* Implanted pacemakers or defibrillators~* Significant neurologic impairments~* Other unstable lower-extremity orthopedic conditions~* Initiated rehabilitation at another facility prior to their first physical therapy session at our facility~* Other lower limb impairment affecting function~* More than one surgery for a tear of the ACL

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Home rehabilitation using Wearable Device (Type: EXPERIMENTAL): Home rehabilitation using Wearable Device(exoRehab)
- Control (Type: ACTIVE_COMPARATOR): Standard home rehabilitation program

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Phase I/II, Open Label, Escalating Dose, Pilot Study to Assess Effect, Safety, Tolerability and PK of Multiple SC Doses of Drisapersen in Patients With Duchenne Muscular Dystrophy and to Assess the Potential for IV Dosing as an Alternative Route of Administration

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Boys aged between 5 and 16 years inclusive.~* Duchenne muscular dystrophy resulting from a mutation correctable by treatment with PRO051.~* Not ventilator dependent.~* Life expectancy of at least six months.~* No previous treatment with investigational medicinal treatment within six months prior to the study.~* Willing and able to adhere to the study visit schedule and other protocol requirements.~Exclusion Criteria:~* Aberrant RNA splicing and/or aberrant response to PRO051, detected by in vitro PRO051 assay during screening.~* Known presence of dystrophin in 5% of fibers in a pre-study diagnostic muscle biopsy.~* Severe muscle abnormalities defined as increased signal intensity in \>50% of the tibialis anterior muscle at MRI.~* FEV1 and/or FVC \<60% of predicted.~* Current or history of liver or renal disease.~* Acute illness within 4 weeks prior to treatment (Day 1) which may interfere with the measurements.~* Severe mental retardation which in the opinion of the investigator prohibits participation in this study.~* Severe cardiac myopathy which in the opinion of the investigator prohibits participation in this study.~* Need for mechanical ventilation.~* Creatinine concentration above 1.5 times the upper limit of normal (age corrected).~* Serum ASAT and/or ALAT concentration(s) which suggest hepatic impairment.~* Use of anticoagulants, antithrombotics or antiplatelet agents.~* Subject has donated blood less than 90 days before the start of the study.~* Current or history of drug and/or alcohol abuse.~* Participation in another trial with an investigational product.

- Gender: MALE
- Minimum Age: 5 Years
- Maximum Age: 16 Years
- Healthy Volunteers: f

Study Arms:
- Drisapersen (Type: EXPERIMENTAL): Extension phase of treatment. Intravenous dosing of drisapersen will be investigated as an alternative route of administration

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Ability to understand the requirements of the trial, to provide written informed consent (including consent for the use and disclosure of research-related health information), willingness and ability to comply with the trial protocol procedures (including required trial visits).~2. The participant participated in trial ARGX-113-1904 and completed the study or has the defined criteria for rollover.~3. Contraceptive use by men and women should be consistent with local regulations regarding the methods for contraception for those participating in clinical trials and:~   1. Male participants:~      Male participants must agree to use an acceptable method of contraception as described in the protocol, from signing the ICF until the last dose of the study drug.~  2. Female participants~Women of childbearing potential (WOCBP) must:~* have a negative urine pregnancy test at baseline before the IMP can be administered,~* agree to use a highly effective or acceptable contraception method (as described in the protocol), which should be maintained at minimum until after the last dose of IMP~Exclusion Criteria:~1. Pregnant and lactating women and those intending to become pregnant during the trial.~2. Participants with clinical evidence of other significant serious disease or participants who recently underwent or have planned a major surgery during the period of the trial, or any other condition in the opinion of the investigator, that could confound the results of the trial or put the participant at undue risk.~3. Known hypersensitivity to any of the components of the administered treatments.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- efgartigimod PH20 SC (Type: EXPERIMENTAL): patients receiving efgartigimod PH20 SC on top of prednisone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy